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Summary Eighteen consecutive patients with measurable locally advanced or metastatic pancreatic adenocar-
cinoma were treated with goserelin (Zoladex) 3.6 mg subcutaneously every 4 weeks. Hydrocortisone 20 millig-
rams twice daily was commenced with the second injection of goserelin. Objective tumour response was
monitored by computerised tomography of the abdomen. There was no objective remission in disease sites.
Serial measurements of serum tumour markers showed no reduction in serum CA 19-9 and CA 195
concentrations. The median duration of survival of all cases was 5 months. Administration of goserelin
resulted in significant reductions in oestradiol, testosterone, androstenedione in males and reductions in FSH
and LH in both males and females. The addition of hydrocortisone resulted in further reductions of
androstenedione and testosterone levels in males. Thus goserelin showed no anti-tumour effect, but concentra-
tions required for direct inhibitory effects may be higher than those required to produce effects on hormone
suppression.
Pancreatic carcinoma is increasing in incidence and
represents a major cause of death due to cancer especially in
middle aged men. Despite significant improvements in imag-
ing techniques a substantial proportion of the patients pres-
ent with advanced disease rendering radical surgery feasible
in only 10-15% of the patients. Overall 5-year survival rates
remain less than 1% and the majority ofpatients die within 6
months of diagnosis. The experience with cytotoxic therapy
with or without radiotherapy in this disease has so far pro-
ved disappointing and is associated with appreciable toxicity
because of the poor nutritional status and advanced age of
many of these patients (Zimmerman, 1981).
Epidemiologic data show that the age-adjusted incidence of
pancreatic cancers is higher in males than females. It has
long been known that human pancreatic tumour cells exhibit
high concentrations of all three specific sex hormone recep-
tors fulfilling a primary requirement for hormone respon-
siveness (Greenway et al., 1981; Corbishley et al., 1984;
Corbishley et al., 1986). Pousette et al. (1987) have also
demonstrated the presence of high levels of human oestrogen
binding protein in normal human pancreas and high to
medium levels in human pancreatic cancer tissue. Tes-
tosterone levels in male patients with carcinoma of the panc-
reas are significantly lower than controls (Robles-Diaz, 1987)
possibly due to the metabolism of testosterone within tumour
cells. Two enzymes, aromatase and 5a-reductase, which con-
vert testosterone to oestradiol and 5a-dihydro testosterone
respectively, are present in malignant pancreatic tissue at a
greater level than those found in normal pancreas (Iqbal et
al., 1983). Experimental work in animals has shown that
testosterone stimulates and oestrogens inhibit the growth of
pre-neoplastic pancreatic foci in male and female rats
(Andren-Sandberg, 1989; Scarpelli & Konishi, 1990). The
mechanism of the effect of sex hormones on growth of
neoplastic lesions and pancreatic cancer is unclear but may
be in part mediated through an altered level of growth
peptides such as gut hormones.
Inhibition of growth of transplanted pancreatic acinar and
ductal cancers in male and female rat and hamster models by
luteinising hormone releasing hormone (LHRH) analogues
and somatostatin has been demonstrated by Redding and
Schally (1984). Low affinity and high affinity LHRH recep-
tors have been identified on the cell membrane and nuclei of
pancreatic tumour cells (Szende et al., 1991). No such bin-
ding sites were detected in normal pancreatic cells (Fekete et
al., 1989). These receptors may be responsible for the trans-
mission of the direct effect of LHRH analogues on the
malignant cells, resulting in the enhancement of apoptosis.
LHRH agonists may also directly inhibit the growth of panc-
reatic tumour cells in vitro (Serrano et al., 1988). It is
therefore possible that LHRH agonists may exert some
therapeutically utilisable direct inhibitory effects on hormone
responsive pancreatic tumour cells in addition to their effects
on sex hormone deprivation.
Goserelin (Zoladex, ICI) is an LHRH agonist which exerts
its endocrine effect by initially stimulating and subsequently
down-regulating the LHRH receptors in the pituitary gland.
Chronic administration results in sex-hormone deprivation
akin to medical or chemical castration (Furr & Woodburn,
1988) and has been shown to be an effective therapy in
premenopausal women with metastatic breast carcinoma and
patients with prostatic carcinoma. Toxicity to goserelin is
minimal and is predictable on the basis of hormonal depriva-
tion. However, LHRH agonists do not produce total inhibi-
tion of sex hormone production because of the secretion of
androgens by the adrenal glands. These adrenal androgens
may be converted to oestrogens by peripheral aromatisation.
Replacement doses of hydrocortisone suppress the produc-
tion ofandrogens from the adrenals which are also the major
source of androgens in post-menopausal women (Harris et
al., 1984). Therefore a combination of goserelin and hydro-
cortisone was used in this study in order to achieve maximal
suppression of circulating androgens and oestrogens.
Accurate objective assessment of tumour response in pan-
creatic cancer is often difficult even with advanced imaging
techniques. A number of serum markers have been proposed
for the detection of pancreatic cancer and monitoring of
disease progression. Approximately 87% of patients with
pancreatic carcinoma exhibit elevated levels of serum CA
19-9 which correlates with tumour stage and burden (Safi et
al., 1989). CA 195 is another circulating tumour marker
which shows high sensitivity for pancreatic cancer (Gupta et
al., 1987). Therefore assessment of response in this study was
performed using both CT scanning and measurements of
serum markers to identify minimal response.
The aims of this study were to assess the response of
carcinoma of pancrease to therapy with goserelin plus hydro-
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cortisone and to determine the influence of such a hormonal
treatment on the circulating hormone levels and serum
tumour markers. Hydrocortisone was given after 1 month of
goserelin to assess whether suppression of adrenal androgens
would contribute significantly to androgen suppression
already induced by goserelin.
Materials and methods
Patients
Eighteen patients with histologically or cytologically verified
unresectable pancreatic adenocarcinoma were entered into
this study. Clinical characteristics of the subjects are shown
in Table I. There were 11 males and seven females with a
median age of 61.5 years (44-73) with all patients naive to
chemotherapy and radiotherapy prior to entry. The study
protocol was approved by the Central Oxford Research
Ethical Committee (COREC) and each patient gave informed
consent prior to starting treatment.
All patients had radiologically measurable disease. Baseline
study parameters included, performance status, full blood
count, serum biochemistry, sex hormone concentrations,
CA19-9 and CA 195 levels, computerised tomogram of the
abdomen, and a chest radiograph. Additional investigations
were performed as clinically indicated.
Treatment
Therapy with goserelin (Zoladex, ICI) was initiated within 4
weeks of establishing the diagnosis. Subcutaneous injections
were administered every 4 weeks and hydrocortisone (20 mg
bid p.o.) was commenced 4 weeks from the first goserelin
injection. Treatment was continued until clinical evidence of
disease progression.
Assessment ofresponse
All patients were evaluated on a monthly basis with a
physical examination and appropriate laboratory studies. CT
scan of the abdomen and any other appropriate imaging tests
were repeated 12 weekly and upon disease progression.
Stable disease was defined as less than 25% increase in the
size of assessable disease over a period of at least 12 weeks.
An increase in the size of the measurable disease sites by
greater than 25% indicated disease progression. Survival
duration in months was measured from the start of treat-
ment.
Table I Characteristics of patients
No Sex/Age PS Operation Disease sites
1 F/63 1 None Panc
2 M/49 1 By-pass Panc
3 F/70 1 Stenting Panc
4 M/54 1 None Panc
5 F/54 2 None Panc
6 M/67 1 None Panc, Li, Ascites
7 M/44 1 By-pass Panc, Li
8 M/73 2 None Panc, Ascites
9 F/59 1 None Panc
10 M/61 1 By-pass Panc
11 M/62 0 Stenting Panc
12 F/57 1 Stenting Panc, Lu
13 M/41 1 Stenting Panc
14 M/61 1 Stenting Panc, Hypercalc
15 F/72 1 None Panc, Ascites
16 M/63 2 None Panc, Li
17 F/69 2 None Panc, P1 Eff, Li
18 M/73 2 None Panc, LN, Bone
P1 Eff
PS Performance Status (ECOG)
Panc Pancreatic mass
Lu Lungs
LN Lymph nodes
P1 Eff Pleural Effusion
Hypercalc Hypercalcaemia
Li Liver
Hormonal assessment
The plasma concentrations of oestradiol, testosterone, and-
rostenedione, FSH and LH were determined in ten patients
using radioimmunoassay (Harris et al., 1982; Ferguson et al.,
1982; Dowsett et al., 1984; Dowsett et al., 1987). Ten ml of
venous blood was withdrawn pre-treatment and repeated 4
and 8 weeks after starting treatment. Plasma was
immediately separated and stored at - 20°C pending analysis.
All plasma samples from one patient were measured simul-
taneously.
Tumour marker determination
Serum CA 19-9 and CA195 were measured 0, 4 and 8 weeks
from starting treatment. Ten millilitres of venous blood was
withdrawn and plasma separated and stored at -20°C pen-
ding analysis. CA 19-9 and CA 195 were assayed by
immunoradiometric assays (Hybritech, UK and Cis, UK
respectively). The cut-off points for normal values were
3OKU.L-' and 10.5KU.L-' for CA 19-9 and CA 195
respectively.
Statistical analysis
A paired two-tailed t-test was used to determine the
difference in hormone concentrations over the observation
period. A statistical package (StatsView 512 +) was emp-
loyed using an Apple Macintosh SE personal computer. AP
value of <0.05 was assumed to represent statistical
significance.
Results
Endocrine effects
Males (eight patients) Plasma testosterone, oestradiol,
FSH, and LH concentrations were all suppressed below basal
levels within 4 weeks of treatment (Table II). The reduction
in the concentration of androstenedione was also statistically
significant (P = 0.2). The addition of hydrocortisone resulted
in a further reduction ofplasma testosterone levels (P = 0.05)
with a statistically reduction in plasma androstenedione
(P = 0.01). There was no significant reduction in either serum
oestradiol (P = 0.7) or LH (P = 0.7) with hydrocortisone,
whereas FSH levels slightly increased after treatment with
hydrocortisone (P = 0.1).
Females (two patients) The two patients on whom endoc-
rine assessment were made were aged 54 years and 67 years
and were both post-menopausal. Treatment with goserelin
resulted in reductions in only FSH and LH levels. Tes-
tosterone, androsternedione, and oestradiol levels were how-
ever no significantly altered following goserelin treatment.
The addition of hydrocortisone resulted in no significant
reduction of testosterone, androstenedione, oestradiol, LH
and FSH levels.
Tumour response
Eight patients who had presented with obstructive jaundice
underwent a surgical bypass procedure or endoscopic biliary
stent insertion prior to commencing treatment. Two patients
required urgent endoscopic relief of obstructive jaundice dur-
ing therapy. The median number of courses of Zoladex
received by the patients was three. Three patients showed
stabilisation of the disease over a period of 9, 13 and 14
months respectively. The remainder of the patients developed
tumour progression with the median duration of overall sur-
vival of 5 months (0.5 to 15 months).
Tumour markers
Tumour markets measurements were undertaken in 14
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Table II The influence of goserelin and hydrocortisone on the plasma concentrations of testosterone, androstenedione,
oestradiol, LH, and FSH. Goserelin was administered in a dose of 3.6 mg subcutaneously every 4 weeks.
Males (n =8) Females (n =2)
Hormone Pre- 4 weeks 8 weeks Pre- 4 weeks 8 weeks
Testosterone (nmol 1-') 14.2 ±7.1 0.7 ±0.4 0.4 ± 0.2 0.6 ± 0.1 0.48 ±0.0 0.6 ± 0.3
(0.0002) (0.03)
Androstenedione (nmol 1-' 5.4 ±3.4 3.8 ±2.2 2.4 ± 2.6 5.2 ± 3.2 4.8 ±1.8 6.5 ± 4.0
(0.2) (0.01)
Gestradiol (pmol I' 92.6 ±41.6 32.3 ±13.0 38.4 ± 27.0 27.5 ± 5.0 26.5 ±7.8 29.5 ± 10.6
(0.002) (0.7)
LH (IU 1') 7.9± 2.9 3.6± 0.9 3.4± 1.4 35.0± 19.8 13.7± 14.6 19.0± 22.7
(0.003) (0.7)
FSH (IU 1-' 7.2 ±5.4 1.1 ±0.3 1.5 ±0.5 12.4 ± 10.8 6.9 ±4.5 4.4 ± 0.6
(0.04) (0.1)
Hydrocortisone was added after 4 weeks (i.e. with second goscrelin) in a dose of 20 mg po bid. P values from two-tailed
t-tests are shown in parentheses.
concentrations of serum CA 19-9 and CA 195 respectively.
Serial measurements of these tumour markers showed a
steady rise in serum concentrations in all patients even in the
two patients who had radiological stabilisation of the disease.
Table III gives the values of the markers prior to and at 8
weeks from starting treatment.
Toxicity assessment
Side effects to this treatment were minimal. No patient com-
plained of reduced sexual function or precipitation of
climacteric symptoms. There were also no untoward effects of
hydrocortisone at the doses used in this study.
Discussion
Despite major advances in the earlier diagnosis of pancreatic
carcinoma, no major impact on survival has been produced
so far. The biochemical studies on pancreatic carcinoma and
hormone responsive models prompted many investigators to
consider hormonal manipulation as a treatment of pancreatic
carcinoma. Tamoxifen and cyproterone acetate were inves-
tigated in a randomised trial which showed no therapeutic
advantage of either drug over untreated controls (Keating et
al., 1989).
The objective of this study was to investigate the contribu-
tion of goserelin and hydrocortisone on tumour response and
on the profile ofperipheral sex hormone levels. The results of
the present study indicate that goserelin in combination with
hydrocortisone is not an effective therapy for pancreatic
Table HII Study results
Tumour markers (KUI11)
No Response Survival Pre-treatment Post-treatmenta
(months) CA 19-9 CA 195 CA 19-9 CA 195
1 PD 12.0 1,705 658 2,839 1,826
2 PD 4.5 1,320 706 5,090 3,618
3 PD 9.5 3,863 1,252 6,271 3,438
4 SD 13.0 85 21 200 44
5 PD 15.0 1,625 1,112 1,729 938
6 PD 4.0 13 2 15 2
7 PD 1.5 31 11 27 11
8 PD 2.75 3,616 1,534 4,396 2,230
9 PD 2.0 663 428 2,575 1,510
10 SD 14.0 43 26 162 56
11 PD 5.0 183 107 783 388
12 PD 5.0 142 50 5,639 3,288
13 PD 5.0 207 96 1,688 522
14 PD 4.0 26 2 113 8
15 PD 2.25
16 PD 0.5
17 PD 0.5 - -
18 SD 9.0
a8 weeks from starting treatment
SD Stable disease PD Progressive disease
carincoma despite the significant lowering of peripheral hor-
mone levels. The only other study on the use of LHRH
agonists in pancreatic carcinoma was reported by Gonzalez-
Barcena et al. (1989) who treated 17 patients with stage IV
pancreatic carcinoma with D-Trp-6-LH-RH. There was im-
provement in symptoms and quality of life with a modest
prolongation of survival. In that study however, no attempt
was made to ascertain objective evidence of tumour response
but they reported one patient with regression in liver metas-
tases.
Goserelin resulted in a significant reduction in plasma
levels of testosterone, oestradiol, FSH and LH in males and
a significant lowering of plasma concentrations of FSH and
LH in females. The number of female subjects studied for the
hormonal effect was only two and hence valid conclusions
cannot be easily achieved. The fall in plasma oestradiol in
males is almost certainly a consequence of lowering plasma
testosterone which is peripherally aromatised to oestradiol.
The addition ofhydrocortisone resulted in a significant fall in
the plasma testosterone levels and a smaller fall in and-
rostenedione levels in male subjects. The plasma concentra-
tion of oestradiol was significantly elevated (to 89 pmol/L)
following treatment with hydrocortisone in one male patient.
This could not be explained on the basis of known hormonal
action of hydrocortisone. The exclusion of this patient from
the analysis results in a lowering of the plasma oestradiol to
am mean of 30.0 ± 16.7 pmol 1' in male subjects following
treatment with hydrocortisone. The small rise in plasma FSH
at 8 weeks of treatment is unlikely to be due to glucocor-
ticoid effect but rather to the known recovery of suppressed
plasma FSH levels which is observed after prolonged treat-
ment with LHRH agonists (Maouris et al., 1991).
There are several possible reasons for the absence of objec-
tive tumour response to LHRH agonists despite effective
suppression of peripheral androgenic hormones. There may
be heterogeneity of human pancreatic tumour cells regarding
the expression of sex hormone and LHRH receptors in panc-
reatic tumour cells. Moreover, there is no clear correlation
between expression of sex steroid receptor and response to
hormonal manipulation. Treatment of hamsters bearing
chemically induced pancreatic carcinomas with LHRH
agonist resulted in a significant down-regulation of LHRH
receptors and insulin-like growth factor receptors (Szende et
al., 1990b). A more complex interplay of peptide growth
factors and sex hormones may control the proliferation of
pancreatic tumour cells in vivo. It is well recognised that
pancreatic tumour cells have receptors for other peptide hor-
mones and growth factors, such as somatostatin and epider-
mal growth factor receptors (Fekete et al., 1989). Carcinogen
induced pancreatic tumours in hamsters showed a
significantly greater response to the combination of somatos-
tatin and LHRH agonist when compared to either drug
administered on its own (Szende et al., 1990a). It is therefore
possible that hormonal stimulation may explain only one
part of pancreatic tumourogenesis.
Given these results with goserelin plus hydrocortisone, the
381382 P.A. PHILLIPS et al.
question remains whether hormonal therapy provides the
alternative to chemotherapy in the treatment of advanced
pancreatic carcinoma. Better understanding is needed on the
contribution of hormonal and peptide growth regulation on
the initiation and promotion of pancreatic carcinoma. To
achieve this it may be necessary to test combinations of
effective hormonal deprivation and modulators of mitogenic
peptide hormone in the treatment of pancreatic tumours in
man. New and more effective therapies are urgently required
to meet this difficult cancer. Novel LHRH analogues may be
investigated which are more potent or can achieve higher
levels and have direct antitumour effects.
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